Intellia Therapeutics, Inc. (NasdaqGM:NTLA) is scheduled to report Q3 earnings results on November 5, 2020.
The company is expected to report earnings of -$0.57/share on revenue of $14.947 million. The consensus earnings per share (EPS) of -$0.57/share is based on a poll of 10 analysts and represents a decline in eps of -15.7% over the same quarter last year, when the company reported earnings of -$0.49/share.
The revenue forecast of $14.947 million based on a poll of 9 analysts implies a year-over-year (YoY) growth in revenue of 40.8%. Last year the company reported $10.616 million in revenue for the quarter.
|Metric||Expected||Prior Year||YoY Change|
Earnings Call Trends
Historically, management has exceeded analyst expectations 6 out of the last 8 tracked quarters, and missed expectations 3 quarters.
What are your expectations from Intellia Therapeutics, Inc. for earnings this quarter? Let us know in the comments!
In the following table, we summarize the company’s stock price movements after earnings releases. The “Price Day Prior” column shows the closing stock price on the day before the earnings report, and the “Price Next Day” column shows the stock price at the end of the trading day after the earnings report. After the last earnings report for the period ending June 30, 2020, the stock price did not react much to the update.
|Report Date||Price Day Prior||Price Next Day||Change %||Result|
|August 6, 2020||$19.65||$19.83||0.9%||Increase|
|May 7, 2020||$13.85||$13.64||−1.5%||Decline|
|February 27, 2020||$12.29||$13.35||8.6%||Increase|
|October 31, 2019||$11.77||$13.60||15.5%||Increase|
The other question to consider is one of earnings manipulation. There is a lot of pressure on management each quarter to deliver on earnings expectations. The Beneish M-Score is a statistical model that provides some insight into whether the company might be manipulating earnings. With a Beneish M-Score of −3.45, the model suggests that the company is not likely to be an earnings manipulator. A value of −3.45 implies a 0.0% chance of earnings manipulation.
Fundamentals And Technical Analysis
Intellia Therapeutics, Inc. is currently trading at $23.94/share, down −4.0% for the day. The company is trading at approximately 88.4% of its 52-week high of $27.07/share. The company’s stock price is up 20.7% since the last earnings report and down −3.8% over the previous week. The company’s 14 Day Relative Price Index (RSI) of 48.38 suggests the company is trading in technically neutral territory. The RSI is considered overbought when above 70 and oversold when below 30.
The current share price implies a price-to-earnings (P/E) multiple of −12.11 and a forward P/E multiple of −11.03.
Intellia Therapeutics, Inc.’s current share price also implies a price-to-book (P/B) multiple of 4.00. The following table summarizes some other key fundamental ratios:
|Last Reported Fiscal Period Key||FY2020.Q2|
|Period End Date||June 30, 2020|
|Stock Price (Current)||$23.94|
|P/E Ratio (Fwd)||−11.0x|
|Total Debt / Total Capital||1.6%|
|Levered Free Cash Flow||-$41.439 million|
|EV / EBITDA||−8.6x|
Intellia Therapeutics, Inc. is a small-cap stock with a market capitalization of $1.406 billion and a total enterprise value of $992.6 million. The company operates in the Healthcare sector and the Biotechnology industry.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.